Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors during the central anxious process, conolidine modulates alternate molecular targets. A Science Improvements study identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://owenk065svz0.activosblog.com/profile